Extended Data Fig. 6: Additional results of pharmacological and optogenetic manipulation in the mesolimbic pathway.
a, Timeline for intracranial injections followed by behavioral assessments (top). Schematic showing intracranial infusions of GDC/API-1 into the NAc followed by METH CPP (bottom). b, CPP scores for subordinate mice with infusion of GDC (n = 6) and vehicle (n = 6). Two-sided unpaired t test, *P < 0.05. c, CPP scores for dominant mice with infusion of API-1 (n = 6) and vehicle (n = 6). Two-sided unpaired t test. d, Changes of social rank before and after intracranial infusion of GDC in subordinates (d) and API-1 in dominants (e) into the NAc (GDC, n = 6; API-1, n = 8; vehicle, n = 6). Two-sided unpaired t test. f, Timeline for mesolimbic activation experiments. g, Schematic of the viral strategy and diagram of optogenetic stimulation during the tube test (left). Representative image in the NAc (right). Scale bar = 200 µm. h, Confirmed positions of optic fibers in the NAc. i,j, Changes of social rank during and after mesolimbic activation in dominant mice; individual data (i) and averaged data (j; ChR2, n = 6; EYFP, n = 6). Two-sided unpaired t test. k, Schematic illustrating mesolimbic activation during METH self-administration in dominant mice. Light was delivered at 20 Hz for 1 s, following an active nose poke. l–n, Nose pokes (l) and infusions (m) across ten sessions and their average number during the last three sessions (n) in the dominant + ChR2 (n = 9) and dominant + EYFP (n = 9) mice. l, Two-way ANOVA, ****P < 0.0001, followed by Tukey’s post-hoc test, ****P < 0.0001; m, ****P < 0.0001; n, two-sided unpaired t test, ****P < 0.0001. Data are represented as mean ± s.e.m. Detailed statistical information is available in Supplementary Table 1.
